Eton Pharmaceuticals, Inc. (ETON)

NGM – Real vaqt narxi. Valyuta: USD

42.61

+0.56 (1.33%)

Bozor ochiq: Aug 12, 2026, 2:24 PM EDT

40.87

-1.18 (-2.81%)

Oldingi bozordan keyin: Aug 11, 2026, 7:42 PM EDT

05.08.2026

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has licensed U.S. rights to rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals (“Auson”). ASN-001 is under development for the treatment of proliferating superficial infantile hemangiomas.

03.08.2026

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Videolar

No Data

There is no data to display

Press-relizlar

05.08.2026

Eton Pharmaceuticals, Inc. (ETON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Videolar

No Data

Press-relizlar

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Videolar

No Data

Press-relizlar

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Search stocks

Eton Pharmaceuticals, Inc. (ETON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Videolar

No Data

Press-relizlar

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Videolar

No Data

Press-relizlar

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001